Xtx Topco LTD Nurix Therapeutics, Inc. Transaction History

Xtx Topco LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$12.02 - $21.3 $127,544 - $226,014	-10,611 Reduced 40.28%	15,729 $328,000
Q1 2024 May 13, 2024	BUY	$7.77 - $15.66 $113,115 - $227,978	14,558 Added 123.56%	26,340 $387,000
Q4 2023 Feb 13, 2024	SELL	$4.25 - $10.71 $43,158 - $108,760	-10,155 Reduced 46.29%	11,782 $121,000
Q3 2023 Nov 13, 2023	BUY	$7.86 - $10.08 $172,424 - $221,124	21,937 New	21,937 $172,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $129,008 - $190,895	-13,084 Reduced 54.79%	10,795 $118,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $294,428 - $473,042	23,879 New	23,879 $311,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.